Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDMA-Assisted Psychotherapy in Healthy Volunteers (MT2)
NCT04073433Phase 1Withdrawn
- Sponsor
- Lykos Therapeutics
- Start
- Dec 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of midomafetamine in post-traumatic stress disorder (PTSD), sponsored by Lykos Therapeutics. Primary endpoint: Self Compassion Scale. Planned start Dec 2024; status: withdrawn.
02
Drugs
midomafetamine
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT04073433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04073433.